Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 3,201–3,300 of 3,704
The Role of GLP-1 Agonists in Weight Management: Barriers, Effectiveness, and Safety Perceptions
Silwal, P., Dilley, A., Adhikari, S., Lusk, J. L., & McFadden, B. R. (2026) · Drugs & Therapy Perspectives · doi:10.1007/s40267-026-01243-y
Zarei, M., & Hajiani, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02196-y
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists
Abid, M., Sheikh, K. S., Ahmad, M. S., & Jiang, H. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s566414
Hailu, K. T., Abriha, F. N., Duguma, Y. M., Haddad, R. R., Liyew, T., & Kasagga, A. (2026) · Cureus · doi:10.7759/cureus.110657 · Cited by 2
Dong, H., Chen, Z., Xing, L., & Li, D. (2026) · Research Square · doi:10.21203/rs.3.rs-9794498/v1
Adamidis, N., Adamidi, S., GEORGAKOPOULOU, V. E., et al. (2026) · Cureus · doi:10.7759/cureus.110805
Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis
Castaneda, R., Bechenati, D., Gutiérrez, R. D. J. R., Espinosa, M. A., Villamarin, J. L., Tama, E., Safwan, N., Fansa, S., Verastegui, A., McNally, A. W., et al. (2026) · Obesity · doi:10.1002/oby.70231 · Cited by 3
Alsuhibani, A. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124591
Dziewierz, A., Kulicka, N., Stolarska, K., Ahmatovic, A., Domienik‐Karłowicz, J., Rulkiewicz, A., & Siudak, Z. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71017 · Cited by 1
Adiposity and cancer: epidemiology, mechanisms and future perspectives
Watts, E. L., Gonzalez‐Feliciano, A. G., Gunter, M. J., Chatterjee, N., & Moore, S. C. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01529-5 · Cited by 4
Yin, Y., Ma, J. H., Liu, D., Duan, W., Cheng, Z., Jiang, H. X., Zhang, Y., Wu, G., Zhuang, H., Gu, W., et al. (2026) · Med · doi:10.1016/j.medj.2026.101183
Rutter, M. K., Mount, J., GIBSON, J. M., Webb, J., Marler, C., Reed, C., Gore, M., Ye, W., Valderas, E. G., Wilding, J. P. H., et al. (2026) · Obesity · doi:10.1002/oby.70247
Diabetes and Weight Management
Perry, M. L. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch13 · Cited by 1
Kardiometabolisches Syndrom – Pathophysiologie, Therapie und Prävention
Raeder, S. (2026) · Kardiologie up2date · doi:10.1055/a-2654-6802
Coulter, A. A., Greenway, F. L., Ramanathan, G., Hubbard, J. R., & Rebello, C. J. (2026) · Obesity Reviews · doi:10.1111/obr.70173
Khalil, W., Bibi, K., Fareed, T., Khan, S., & Chiran, J. (2026) · Cureus · doi:10.7759/cureus.110952 · Cited by 2
Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence
Parlati, A. L. M., Martini, L., Nardi, E., Carluccio, R., Parlati, L. E., Madaudo, C., & Filardi, P. P. (2026) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468261460202 · Cited by 3
Beig, J., Ta, J., Jones, S., Scott, E., Sofi, K., Osler, F., Jansen, M., & Chhabra, P. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70059 · Cited by 1
Interruption of Early Cardiovascular Risk Pathways With GLP-1-Based Therapy for Obesity
Everett, B. M., & Ostrominski, J. W. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.011
Hunter, T. M., Makin, H., Gerber, C., Bottomley, C., He, X., Pisani, S., Shepherd, M., Collins, E., Golden, A. K., & Bays, H. E. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100288 · Cited by 1
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
Nephroprotektion – Diabetes und Adipositas
Boger, L. (2026) · Diabetes aktuell · doi:10.1055/a-2881-6950
Moka, A. O., Nwachi, D., Igboanude, C. H., Adelaja, A. T., Olabode, M. D., & Okpaluba, O. C. (2026) · Research Square · doi:10.21203/rs.3.rs-9795190/v1
Bergia, R. E., Brown, A. W., Braun, M. M., & Messina, M. J. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100689 · Cited by 1
Xiao-yu, Z., Wu, Q., Lu, H.-L., Xie, J.-J., Zhang, Y., Xu, Y., Guo, M., & Teng, F. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02163-7 · Cited by 2
Long-term effects of weight-reducing drugs in people with hypertension
Spary-Kainz, U., Posch, N. A. S., Radl-Karimi, C., Jeitler, K., Krenn, C., Siebenhofer, A., Berghold, A., Horvath, K., Winterholer, S., & Semlitsch, T. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub6 · Cited by 1
Anti-obesity drugs: The new frontier of weight loss: Revolution or risk?
Sharma, S. P. (2026) · BJKines National Journal of Basic & Applied Sciences · doi:10.25259/bjkines_13_2026 · Cited by 1
Zeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
Qiao, Z., Du, Y., Lou, J., & Qu, Y. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-00998-w
Guo, A., Krishnan, S., Patel, J., Nayeri, R., Chatterjee, D., Srivastava, P. K., & Nayeri, A. (2026) · Next research. · doi:10.1016/j.nexres.2026.102044
Engineering single-dose plasmid DNA for sustained in vivo delivery of designer incretins
Gary, E. N., Gao, Y., Hojecki, C. E., Tursi, N. J., Zhang, W., Goldman, A. R., Laenger, N., Tomirotti, M., Khan, M. S. A. A., Sahai, R., et al. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.05.023
Alaycı, B., & Gerçek, Ö. Z. (2026) · BMC Endocrine Disorders · doi:10.21203/rs.3.rs-9973131/v1
Hill, C., Rodriguez, N. A., & Scott, J. D. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_14
Reoperative Options After Single Anastomosis Duodenal Switch
Torres, A. J., Romera, J. L., Ruano, A., et al. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_44
Maximizing Obesity Therapy: Strategic Use of Anti-obesity Pharmacotherapy
Bartfield, J. K., & Bonnecaze, A. K. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_70
Read, M., & Husain, F. A. (2026) · Surgical Clinics of North America · doi:10.1016/j.suc.2026.04.005
Teli, B., Sathe, S., Kalra, R., Mahajan, V., Mehta, A., Shinde, R., Kunwar, B., Kahale, P., Sinkar, A., Palimkar, P., et al. (2026) · Cureus · doi:10.7759/cureus.111322
Weight Loss Following Liraglutide Therapy in a Patient With Smith-Magenis Syndrome: A Case Report
Garg, D. K., & Wei, J. (2026) · Cureus · doi:10.7759/cureus.111313
Ahn, J., Rhee, H., Chung, H. J., Hong, E., & Ryu, J. C. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e21
Treating Severe Obesity: A Medical Perspective
Paknikar, S. S., & Muthusamy, K. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03668-3
Mady, R., Tafazal, H., Soliman, H., Ramadan, A., & Hajaj, M. (2026) · Cureus · doi:10.7759/cureus.111445
Baletic, D., Božić, N., Kusturica, M. P., Tomić, L., Todorović, V. I., Vasović, S., & Rašković, A. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2690834 · Cited by 1
Vignera, S. L., Fioriglio, C., & Condorelli, R. A. (2026) · Diagnostics · doi:10.3390/diagnostics16131979
Carducci, A., Matteo, P. D., Ferri, C., & Grassi, D. (2026) · Cureus · doi:10.7759/cureus.111508
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists
Rosen, C. B., & Gee, D. W. (2026) · Advances in Surgery · doi:10.1016/j.yasu.2026.03.011
Zhang, J.-J., Tan, Y.-S., Zhang, C.-L., Gui, Y., Yan, F.-Z., Hou, J., Xiang-xuan, L., Kong, H., Guo, M.-R., Cui, Y.-F., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.178787 · Cited by 1
GLP-1 Receptor Agonists beyond Glycemic Control: Physiology and Pharmacological Evidence
Amate, P. (2026) · Open Journal of Pharmacology and Pharmacotherapeutics · doi:10.17352/ojpp.000029
Az elhízás és a testsúlycsökkentés szerepe obstruktív alvási apnoéban
Horváth, G., Berner, S. C., Bardóczi, A. B., Csoma, B., Müller, V., & Horváth, G. (2026) · Orvosi Hetilap · doi:10.1556/650.2026.33589
The Ageing Adipose Paradox: Implications for Metabolic Health
Matar, D. B., Elahi, M. A., Nassar, W. K., Alotaibi, M. I., Murphy, D., Fakhoury, H. M. A., & Aljada, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71037 · Cited by 1
Dubaj, M., Piech, B., `Mzabi, S. K., Judzińska, A., Ignarska, J., Trojanowska, E., Sobczyńska, K., Terbosh, M., Osipowska, J., & Kwolek, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5603
Preoperative Weight Loss: Helpful, Harmful or Irrelevant?
Hanipah, Z. N., & Schauer, P. R. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08763-6
Onishi, A., Onodera, T., Sugaya, S., Matsushita, T., Komorisono, M., Shin, J., Nishitani, S., Fukuhara, A., & Shimomura, I. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158522
Elma, Y., & Topaloğlu, Ö. (2026) · Hitit Medical Journal · doi:10.52827/hititmedj.1848166
Simental‐Mendía, L. E., Barragán‐Zuñiga, L. J., & Reyes-Avitia, V. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00812-6
Babazadeh, D., Therrien, S., Fitch, A., & Steinberg, F. M. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100292 · Cited by 1
Alfadda, A. A., Isnani, A. C., Eldin, M. S., Joy, S. S., Awwad, H. M., Othman, O. M., Elkhateb, H., & Domero, K. C. (2026) · Obesities · doi:10.3390/obesities6040046
Patel, H., Babli, S. A., Shah, S., Khambholja, S. H., Lingadahalli, T. D., Villarson, C., Rizwanullah, U., Kumarsivarajah, S., Masood, A., Rahming, N., et al. (2026) · Cureus · doi:10.7759/cureus.111786
Obesity and obstructive sleep apnea: from pathophysiology to current clinical approaches
Treptow, E. C., Carneiro, G., Andersen, M. L., Drager, L. F., & Genta, P. R. (2026) · Respiratory Research & Clinical Practice · doi:10.36416/1806-3756/e20250314
Body Composition Changes During GLP-1 Receptor Agonist Therapy in Pediatric Obesity: A Pilot Study
Pascu, B. M., Bojoga, I., Balanescu, A., Balanescu, P. C., & Gherghina, I. (2026) · Metabolites · doi:10.3390/metabo16070460 · Cited by 2
邓晨, Fan, Z., Xu, Y., Cao, M., Liao, J., & Meng, M. (2026) · Bioengineering · doi:10.3390/bioengineering13070767 · Cited by 2
Ghusn, W., Fansa, S., Tama, E., Añazco, D., Espinosa, M. A., Villamarin, J. L., Cifuentes, L., Gala, K. S., Hurtado, M. D., & Acosta, A. J. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.02.006 · Cited by 3
Hundal, J., Linz, M. O., Anikreddy, S., Sengupta, S., Zhou, K., & Maiti, B. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00061 · Cited by 1
Metcalfe, R., Yan, Y., Alam, S., Dyrkton, N., Wilbur, J. D., Abdul-Karim, R., & Park, J. J. H. (2026) · Value in Health Regional Issues · doi:10.1016/j.vhri.2026.101666
Monami, M., Ragghianti, B., & Mannucci, E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71046
Medikamente zur Behandlung von Essstörungen und Adipositas
Himmerich, H. (2026) · Springer eBooks · doi:10.1007/978-3-662-72452-1_9
Qiu, L., Liu, J., & Hu, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1870649 · Cited by 4
Khalil, I., Sarker, P., Nur, N., Hossain, M. S., Khalid, A. A., Al-Badri, S. G., Akter, M. M., Das, M., & Rahman, M. T. (2026) · Hepatology International · doi:10.1007/s12072-026-11122-3
Szerenos, N., Woroniecka, N., Trocka, D., Kozłowska, A., Przybysz, K., Stadnik, L., Zienkiewicz, N., Rachoń, J., Dzwonkowska, A., & Dzwonkowski, J. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6150
Kim, H., Chae, J. H., & Moon, H. Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02141-z
CINNAMON AGAINST OBESITY – A SYSTEMATIC REVIEW
Zbrożek, M., Maruchniak, H., Marzec, W., Biedroń, P., Skrzypek, A., Hutkowski, M., Chwostek, Z., Kosiarski, B., Markowicz, P., & Biłyk, K. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5772
Galasso, M., Verde, L., Patrone, R., Ragozzino, G., Annunziata, G., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1855886 · Cited by 2
Sarcopenia in Asian Patients in the Era of SGLT2i and GLP-1RA: A Clinical Concern?
Alam, A., Salman, M., Mahfooz, S., & Mahmood, S. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_30_26
Im, S., Lee, J., & Kim, J.-E. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070826
Gorban, V. V., Витальевна, Г. Е., & Kocherga, P. E. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-194
Joshi, D. M. (2026) · Cureus · doi:10.7759/cureus.112135
Mahaboob, L., Shehab, A., Buraiki, H. A. A., Iblasi, A. S., & Farghaly, W. K. T. (2026) · Romanian Medical Journal · doi:10.37897/rmj.2026.2.12
Drouin‐Chartier, J., Caron, A., & Lessard‐Lord, J. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100295
Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review
López-Delgado, D. S., Reyes-Zermeño, M. G., Lemus, E. D. S., Acosta-Celis, C. G., Kantún-Marín, M. A., Gomez-Lujan, M., Fallaza-Moya, K., Muñoz-Chuquilín, O., Levano, S. E. T., Gutierrez-Chavez, G., et al. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1803474 · Cited by 2
Hypoglycemic Ketoacidosis in Nondiabetic Patients on Tirzepatide
Dhapola, V. S., Pundir, S., & Pandey, V. (2026) · Indian Journal of Medical Specialities · doi:10.4103/injms.injms_325_25
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
Bao, J., & Wang, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71071
Wu, J., Zheng, W., Qi, Q., He, C., Zhai, C., & Fan, H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm51234 · Cited by 1
Beyond lifestyle alone: obesity treatment and the future of cardiovascular prevention
Lotto, R. R., & Pickering, M. (2026) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2026.0039
Real‐World vs. Randomized Trial Evidence for Incretin‐Based Therapies: A Narrative Review
Bloomgarden, Z. T. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70248 · Cited by 1
GLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways
Lindquist, P., Dijkhof, L. R. H., Drzazga, A. K., Sabatier, P., Stępniewski, T. M., Granlund, L., Lechner, M. Y., Zhong, Y., Gasbjerg, L. S., Hartmann, B., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.06.003
Geraci, C., Cannarella, R., Morello, V., Paternò, V., Petrina, S. M., Esposito, R., Geraci, G., Condorelli, R. A., Vignera, S. L., & Calogero, A. E. (2026) · Cancers · doi:10.3390/cancers18142212
James-Okoro, P.-P., Field, J., Davies, G., Pearce, A., Al‐Sabah, S., Lim, K. N., Ladds, G., Hornigold, D. C., Gribble, F. M., & Reimann, F. (2026) · Peptides · doi:10.1016/j.peptides.2026.171507 · Cited by 1
Hunter, T. M., Al‐Zubeidi, T., Gerber, C., Collins, E., Vardavoulia, A., Lin, A., He, X., Shepherd, M., Fitch, A., & Bays, H. E. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100298
Miller, L. B., Dellen, M. J., Gilbert, E., Faler, B. J., Brockmeyer, J. R., & Mandia, J. J. (2026) · Military Medicine · doi:10.1093/milmed/usag316
A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications
Chao, A. M., Asante, R., Sersah, M. E., Jahangir, U. A., Peary, A., & Kudaya, D. Q. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70162
Hyperuricemia, gout and obesity: should weight management be more of a focus in gout management?
Scilletta, S., Marco, M. D., Bosco, G., Barbagallo, F. D. G., Galeano, F., Tumminia, A., Milluzzo, A., Gaudio, A., Frittitta, L., Scicali, R., et al. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104860
Pendrey, A., Sierra, J. A. R., Lobo, F. A. A., Herrera, E. J. R., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03702-4
Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Labate, A. M., Cimino, E., Giacomelli, L., Ettori, S., Oladeji, O. A., & Agosti, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146170 · Cited by 2
Bariatric surgery should lead South Africa’s obesity treatment strategy
Smit, J., & Lübbe, J. (2026) · South African Journal of Surgery · doi:10.36303/sajs.04659
Hunter, T. M., Leith, A., Harrison, L., Gerber, C., Raikar, S. K., Seth, E., & Artime, E. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100300 · Cited by 1
Kitamoto, T., Yoshino, M., Shingaki, T., Oura, T., Valderas, E. G., & Dunn, J. P. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2695047
Yalçın, N. (2026) · Cukurova Anestezi ve Cerrahi Bilimler Dergisi · doi:10.36516/jocass.1933450
Spiazzi, B. F., Zingano, C. P., Colpani, V., & Gerchman, F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113431 · Cited by 3
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.